— *Council Implementing Regulation (EU) No 1245/2011 of 1 December 2011 implementing Regulation (EU) No 961/2010 on restrictive measures against Iran;*

— *Regulation No 267/2012;*

3. *Declares that the effects of Council Decision 2010/413/CFSP of 26 July 2010 concerning restrictive measures against Iran and repealing Common Position 2007/140/CFSP, as amended by Decision 2011/299 and Decision 2011/783, are maintained as regards, on the one hand, Ocean Capital Administration and the other applicants whose names appear in the annex to this judgment and, on the other hand, IRISL Maritime Training Institute, Kheibar, Kish Shipping Line Manning and IRISL Multimodal Transport, until the annulment of Regulation No 267/2012 takes effect;*

4. *Orders the Council of the European Union to bear, in addition to its own costs, the costs incurred by Ocean Capital Administration and the 35 other applicants whose names appear in the annex to this judgment and by IRISL Maritime Training Institute, Kheibar, Kish Shipping Line Manning and IRISL Multimodal Transport.*

([1]) OJ C 290, 1.10.2011.

Judgment of the General Court of 22 January 2015 — Teva Pharma and Teva Pharmaceuticals Europe v EMA

(Case T-140/12) ([1])

(Medicinal products for human use — Orphan medicinal products — Application for marketing authorisation for the generic version of the orphan medicinal product imatinib — EMA decision refusing to validate the application for marketing authorisation — Market exclusivity)

(2015/C 081/16)

Language of the case: English

Parties

Applicants: Teva Pharma BV (Utrecht, Netherlands); and Teva Pharmaceuticals Europe BV (Utrecht) (represented by: D. Anderson, QC, K. Bacon, Barrister, G. Morgan and C. Drew, Solicitors)

Defendant: European Medicines Agency (EMA) (represented by: T. Jabłoński, M. Tovar Gomis and N. Rampal Olmedo, acting as Agents)

Intervener in support of the defendant: European Commission (represented by: E. White, P. Mihaylova and M. Šimerdová, acting as Agents)

Re:

Application for annulment of the EMA's decision of 24 January 2012 refusing to validate the applicants' application for authorisation to place imatinib Ratiopharm, a generic version of the orphan medicinal product imatinib, on the market, in so far as concerns therapeutic indications for the treatment of chronic myeloid leukaemia.

Operative part of the judgment

The Court:

1) *Dismisses the action.*

2) *Orders TEVA Pharma BV and Teva Pharmaceuticals Europe BV to bear their own costs and to pay the costs incurred by the European Medicines Agency (EMA).*

3) *Orders the European Commission to bear its own costs.*

([1]) OJ C 165, 9.6.2012.